Post-COVID syndrome, inflammation, and diabetes.
COVID-19
Long COVID
New-onset diabetes
Newly diagnosed diabetes
Post-COVID syndrome
SARS CoV-2
Syndemia
Type 2 diabetes
Journal
Journal of diabetes and its complications
ISSN: 1873-460X
Titre abrégé: J Diabetes Complications
Pays: United States
ID NLM: 9204583
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
09
07
2022
revised:
30
08
2022
accepted:
02
10
2022
pubmed:
14
10
2022
medline:
9
11
2022
entrez:
13
10
2022
Statut:
ppublish
Résumé
The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new-onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called "Long COVID" or "Post-COVID Syndrome". It is thought that a chronic, low-grade inflammatory and immunologic state persists during this phase, which may last for weeks or months. Although numerous insights have been gained into COVID-related hyperglycemia and diabetes, its prediction, course, and management remain to be fully elucidated.
Identifiants
pubmed: 36228563
pii: S1056-8727(22)00248-3
doi: 10.1016/j.jdiacomp.2022.108336
pmc: PMC9534783
pii:
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
108336Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.